Corvus Pharmaceuticals Inc
Corvus Pharmaceuticals Inc (CRVS) Option Chain
Read more
Tracking the CRVS option chain helps you see every strike and expiry on Corvus Pharmaceuticals Inc in one view, so you can quickly identify contracts that fit your thesis and your risk. It lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of CRVS options activity at a glance. Use our scanner to monitor the CRVS option chain in real time and filter for the trades that actually meet your criteria.
An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For CRVS stock options, the chain shows call and put data side by side, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading it well means looking beyond the last price. Implied volatility by strike, volume to open interest ratios, and bid ask spreads all show where CRVS options are being actively traded, and where they are not.
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer.
| CALLs | PUTs | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prob. OTM % | Open Interest | Volume | Extrinsic Value | Intrinsic Value | Bid | Ask | Strike | Moneyness % | Bid | Ask | Intrinsic Value | Extrinsic Value | Volume | Open Interest | Prob. OTM % |
| 5.98 | 81 | 0 | 1.08 | 1.60 | 0.45 | 4.90 | 9.00 | -15.41 | — | 0.70 | 0.00 | 0.70 | 0 | 30 | 94.02 |
| 29.17 | 1,011 | 0 | 0.30 | 0.60 | 0.05 | 1.75 | 10.00 | -6.02 | — | 0.75 | 0.00 | 0.75 | 0 | 54 | 70.83 |
| 64.18 | 288 | 5 | 0.50 | 0.00 | — | 0.50 | 11.00 | +3.38 | 0.20 | 1.20 | 0.40 | 0.30 | 0 | 10 | 35.82 |
| 88.41 | 351 | 10 | 0.30 | 0.00 | — | 0.30 | 12.00 | +12.78 | 0.50 | 2.45 | 1.40 | 0.07 | 0 | 36 | 11.59 |
| 97.51 | 26 | 0 | 1.30 | 0.00 | — | 1.30 | 13.00 | +22.18 | 0.20 | 4.90 | 2.40 | 0.15 | 0 | 1 | 2.49 |
As of Nov 16, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV Rank63.49% Moderate
- Market cap (M$)894
- 52 weeks high-60.67%
- 52 weeks low65.88%
- Analyst recommendationStrong Buy
1.14 - Target price$31.50
197.17% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-05
- P/E—
- Future P/E—
- EPS (ttm)-0.71
- EPS growth next 5 years—
As of Nov 16, 2026